Interview with Sree Haran, Senior Partner, TranScrip Partners
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Comopany Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Australia Pty Ltd
Suite 1, Level 5, 123 Epping Rd
North Ryde, NSW 2113
Australia
Phone: +61 2 8875 3900
Fax: +61 2 9889 1162
www.biogenidec.com.au
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
See our Cookie Privacy Policy Here
